Sunday, November 12, 2006 4:15pm -
4:30pm. 2003 Microvolt T-Wave Alternans Identifies ICD Benefit in Ischemic
Cardiomyopathy Patients |
|
Keywords: |
Implantable
cardioverter defibrillator, Arrhythmias, Ischemic heart disease,
Cardiomyopathies |
Disclosure
Block: |
P.S.
Chan, None; D.J. Kereiakes, None; C. Bartone,
None; T. Booth, None; E.J. Schloss, None; T.
Waller, None; E. Chung, None; S. Menon, None; B.K.
Nallamothu, None; T. Chow, Medtronic, St. Judes, Modest,2.
Research Grant (includes principal investigator, collaborator or consultant
and pending grants as well as grants already received). |
|
|
Abstract:
|
Objective: To assess if implantable cardioverter-defibrillators
(ICDs) have different mortality benefits among patients with ischemic
cardiomyopathy who screen microvolt T-wave alternans (MTWA) negative and
non-negative (positive and indeterminate). Background: MTWA has been
proposed as an effective tool for risk stratification. However, no studies
have examined whether ICD benefit differs by MTWA group. Methods: We
developed a prospective cohort of 768 patients with ischemic cardiomyopathy
(LVEF<35%) and no prior sustained ventricular arrhythmia, of which
392 (51%) received ICDs. Mean follow up was 27+12 months. Propensity
scores for ICD implantation based on the three variables (EPS testing, QRS
duration >120ms, and abnormal Holter) most likely to influence
defibrillator implantation were developed for each MTWA cohort. Multivariable
Cox analyses which controlled for propensity score, demographics, clinical
variables, and medication usage evaluated the degree to which ICDs decreased
mortality risk for each MTWA group. Results: We identified 514 (67%)
patients with a non-negative MTWA test. C-statistics for the propensity
scores showed good discrimination [C=0.81 (MTWA non-negative); C=0.78 (MTWA
negative)]. After multivariable adjustment, ICDs were associated with lower
all-cause mortality in MTWA non-negative patients [hazard ratio (HR)=0.45
(95% CI: 0.27, 0.76); p=0.003] but not in MTWA negative patients [HR=0.85
(0.33, 2.20); p=0.73] (p-value for interaction=0.04), with the mortality
benefit in MTWA non-negative patients largely mediated through arrhythmic
mortality reduction [HR=0.30 (0.13, 0.68); p=0.004]. The number needed to
treat with an ICD for 2 years to save one life was 9 among MTWA non-negative
patients and 76 among MTWA negative patients. Conclusion: In patients
with ischemic cardiomyopathy and no prior history of ventricular arrhythmia,
mortality reduction with ICD implantation differs by MTWA status, with
implications for risk stratification and health policy. |